According to a recent media report in the Economic Times, the discussions, however, face a valuation hurdle. While Tata 1mg was valued at $1.25 billion post-money in its 2022 round, potential investors are reportedly pushing for a revised valuation in the $750–800 million range. In addition, some are demanding board seats and additional rights, conditions the company is unwilling to accept.
If the deadlock continues, Tata Sons may step in with about $75 million in a down round, or the company may opt for a smaller fundraising exercise. Sources suggest that Tata 1mg currently needs around $125 million in fresh capital.
“1mg continues to perform strongly, with smooth execution and no major challenges on the delivery front,” a source told ET. “Our integration with Tata Neu (positioned as a super app) has further accelerated growth and significantly scaled up the business. Investor interest in 1mg has always been encouraging … funding is not a concern for us and will be secured in line with the best available options.”
Tata Digital, which owns about 63% of Tata 1mg, remains the company’s majority shareholder. Other key investors include Sequoia, Intel Capital, Omidyar Network, and the Bill & Melinda Gates Foundation. In FY25, Tata 1mg reported consolidated revenue of ₹2,392 crore, up 22% year-on-year, while reducing its consolidated loss to ₹276 crore from ₹313 crore in FY24.
The company is also expanding its portfolio beyond e-pharmacy into diagnostics, consultations, and offline presence, while enhancing delivery services that promise 4–5 hour fulfillment in many cities and 30-minute express delivery for select orders.
ET reports that Tata declined to comment on the fundraising talks. Meanwhile, Permira, CPPIB, and ChrysCapital either declined or said they were unaware of the deal, while Novo Holdings did not respond.
Although online pharmacies account for only 3–5% of India’s overall pharma market, investors continue to see significant growth potential despite thin margins, regulatory risks, and heavy losses faced by competitors.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.